Increasing evidence suggests that neuroinflammation contributes to the pathophysiology of
many neurodegenerative diseases, especially Alzheimer's disease (AD). Molecular imaging …

The field of molecular imaging has experienced significant advances in the area of
Alzheimer disease (AD), the most significant being the development of PET radiotracers for …

An early detection and intervention for dementia represent tremendous unmet clinical needs
and priorities in society. A shared feature of neurodegenerative diseases causing dementia …

Recent progress in molecular imaging has provided new important knowledge for further
understanding the time course of early pathological disease processes in Alzheimer's …

There is increasing use of neuroimaging modalities, including PET, for diagnosing
dementia. For example, FDG-PET demonstrates hypometabolic regions in the posterior …

Purpose [18 F] FDG is a commonly used neuronal injury biomarker for early and differential
diagnosis of dementia. Typically, the blood supply to the brain is closely coupled to glucose …

Purpose To quantify the effect sizes of regional metabolic and morphometric measures in
patients with preclinical and mild Alzheimer disease (AD) to aid in the identification of …

With the advent of biomarkers in clinical management and findings of molecular
neuroimaging studies in the evaluation of patients with suspected dementia, the impact of …

Purpose of review Alzheimer's disease (AD) and frontotemporal dementia can often be
diagnosed accurately with careful clinical history, cognitive testing, neurological …

Background In recent years, longitudinal studies of Alzheimer's disease (AD) have been
successively concluded. Our aim is to determine the efficacy of amyloid‐β (Aβ) PET in …